OncoGenex Cuts Half of Workforce, Leaving 27 Employees
Luke Timmerman8/21/08
OncoGenex Pharmaceuticals, (NASDAQ: OGXI) the developer of cancer drugs, said today it has cut half of its workforce as part of the merger between its predecessor company and Bothell, WA-based Sonus Pharmaceuticals. After the job cuts, the company will have 27 full and part-time employees. OncoGenex stock fell 3.6 percent to $4.82 in its first day of trading.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
